NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
- First Posted Date
- 2015-05-05
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 94
- Registration Number
- NCT02434081
- Locations
- 🇧🇪
University Hospital Leuven, Leuven, Belgium
🇩🇪Thoracic Oncology Centre Munich, Munich, Germany
🇳🇱VUMC, Amsterdam, Netherlands
IBCSG Trial 22-00 Serum Substudy
- Conditions
- Breast Cancer
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 136
- Registration Number
- NCT02393833
- Locations
- 🇮🇹
Istituto Europeo di Oncologia (IEO, Milano, Italy
Afatinib in NSCLC With HER2 Mutation
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 13
- Registration Number
- NCT02369484
- Locations
- 🇩🇪
Universitätsklinikum Köln, Köln, Germany
🇳🇱NKI-AVL, Amsterdam, Netherlands
🇪🇸Vall d'Hebron University Hospital, Barcelona, Spain
Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer
- Conditions
- Early Breast Cancer
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 518
- Registration Number
- NCT02308085
- Locations
- 🇺🇸
Cedars Sinai Medical Centre, Los Angeles, California, United States
🇺🇸Stanford Cancer Institute, Palo Alto, California, United States
🇺🇸Sharp Memorial Hospital, San Diego, California, United States
Survival imProvement in Lung cancEr iNduced by DenOsUmab theRapy
- Conditions
- Lung Cancer Non-small Cell Stage IV
- Interventions
- Other: None, standard chemotherapy only
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 595
- Registration Number
- NCT02129699
- Locations
- 🇦🇹
Univ. Klinik für Innere Medizin V, Innsbruck, Austria
🇦🇹KH der Elisabethinen Linz, Linz, Austria
🇦🇹AKH Wien, Wien, Austria
Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
- First Posted Date
- 2014-05-02
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 58
- Registration Number
- NCT02129556
- Locations
- 🇦🇺
Peter MacCallum Cancer Centre, East Melbourne, Australia
🇦🇺Westmead Hospital, Westmead, Australia
🇦🇹Medical University of Vienna, Vienna, Austria
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
- Conditions
- Limited Stage Small Cell Lung CancerSmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 222
- Registration Number
- NCT02046733
- Locations
- 🇦🇺
Bendigo Hospital, Bendigo, Australia
🇦🇺Coffs Harbour Health Campus, Coffs Harbour, Australia
🇦🇺Royal Brisbane and Women's Hospital (QLD), Herston, Australia
TRial on the Endocrine Activity of Neoadjuvant Degarelix
- Conditions
- Breast Cancer Invasive Nos
- Interventions
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2019-05-29
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 51
- Registration Number
- NCT02005887
- Locations
- 🇮🇹
Azienda Ospedaliero-Universitaria Policlinico S. Orsola-Malpighi di Bologna, Bologna, Italy
🇮🇹Ospedali Galliera, Genova, Italy
🇮🇹Istituto Europeo di Oncologia, IEO, Milano, Italy
Schedules of Nab-Paclitaxel in Metastatic Breast Cancer
- First Posted Date
- 2012-12-10
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 258
- Registration Number
- NCT01746225
- Locations
- 🇧🇪
CHR de la Citadelle, Oncology-Haematology Unit, Liège, Belgium
🇧🇪CHU Sart Tilman, Medical Oncology, Liège, Belgium
🇧🇪Centre Hospitalier Peltzer-La Tourelle, Department of Clinical Cancerology, Verviers, Belgium
Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.
- First Posted Date
- 2012-07-30
- Last Posted Date
- 2022-08-24
- Lead Sponsor
- ETOP IBCSG Partners Foundation
- Target Recruit Count
- 81
- Registration Number
- NCT01652469
- Locations
- 🇦🇹
Krankenhaus Hietzing, Wien, Austria
🇧🇪Institut Jules Bordet, Brussels, Belgium
🇩🇰Aarhus University Hospital, Aarhus, Denmark